AstraZeneca PLC (AZN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges
AstraZeneca PLC (AZN) reports a robust 21% revenue increase for 2024, while navigating market challenges and strategic advancements.
AstraZeneca PLC (NASDAQ:AZN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, expectations were $1.07. Pascal Soriot: Thank you, Andy. Welcome everybody.
GrafTech International (EAF) Q4 2024 Earnings Call Transcript
Operator Good morning, ladies and gentlemen, and welcome to the GrafTech fourth-quarter 2024 earnings conference call and webcast. [Operator instructions] This call is being recorded on Friday, February 7th,
AstraZeneca Plc (AZN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Feb 06, 2025, 6:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants
Byrna Technologies Inc. (BYRN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call February 7, 2025 9:00 AM ET. Company Participants. Bryan Ganz - CEO Lauri Kearnes - CFO. Conference Call Par
Proto Labs (PRLB) Q4 2024 Earnings Call Transcript
Greetings, and welcome to the Proto Labs fourth quarter and fiscal year 2024 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation.
AstraZeneca gains as Q4 results clear China overhang
AstraZeneca (AZN) stock rises as its Q4 results which exceeded Street forecasts address concerns over its China investigation ...
BioSpace1d
AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...
AstraZeneca reports Q4 core EPS $2.09
Reports Q4 revenue $14.89B, consensus $13.34B. The company said, “Our company delivered a very strong performance in 2024 with Total Revenue ...
AstraZeneca outlines $3.2 dividend hike and anticipates strong 2025 growth
Q4 2024 Management View CEO Pascal Soriot highlighted a strong 2024 performance with total revenue up 21% and core EPS growth at 19%, reflecting solid business momentum supported by pipeline ...
Why AstraZeneca Topped the Market on Thursday
AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a meaty 24% improvement over Q4 ...
precisionmedicineonline1d
AstraZeneca Optimistic About Phase III Capivasertib Data in 2025, Reports Strong Q4 Product Growth
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
Business Weekly1d
AstraZeneca leads FTSE charge with shares surge and higher dividend
Growing at a rate of knots from the Cambridge Biomedical Campus, AstraZeneca hoisted its market cap to £183.58 billion and ...
AstraZeneca reports Q4 core EPS $2.09, up 49% at CER
Reports Q4 reported EPS 97c vs. 62c last year. Reports Q4 revenue $14.89B, consensus $14.28B. Pascal Soriot, CEO, AstraZeneca (AZN), ...